Harmony Prenatal Test Now Performed in Taiwan by Phoebus Genetics

Pleasanton, CA – June 16, 2016 - Roche (SIX: RO, ROG; OTCQX:RHHBY) announced that Phoebus Genetics, a preeminent genetics laboratory based in Taiwan, is offering Harmony, the leading global non-invasive prenatal test for assessing the probability of fetal trisomy 21, 18, 13, and sex chromosome aneuploidy. As the third commercial laboratory licensed to perform Harmony in the Asia Pacific region, Phoebus is excited to partner with global diagnostics leader, Roche, to offer the exceptional accuracy of the Harmony Prenatal Test in Taiwan.

“After decades of being on the cutting edge of molecular techniques, we are particularly interested in early detection, as demonstrated by our success in the identification of early stage, asymptomatic cancers.” explains Dr. Yi-Ning Su, CEO of Phoebus Genetics. “We view the Harmony Prenatal Test as a key component of our focus on early and accurate detection. Our partnership with Roche Diagnostics provides us the opportunity to offer healthcare providers and expecting parents with exceptional accuracy, affordability, and peace of mind.”

The Harmony Prenatal Test is performed in the Phoebus laboratory with the Harmony Kit and the Ariosa cell-free DNA System.

About the Harmony Test

The Harmony Prenatal Test is a blood screening test for pregnant women that can be used as early as 10 weeks into pregnancy. By evaluating fetal cell-free DNA found in maternal blood, including accurate measurement of the fetal fraction of DNA, the test assesses the probability of Trisomy 21 (Down syndrome) and other common fetal aneuploidies. Harmony has been validated by a robust clinical data set and is supported by clinical studies in more than 23,000 women ranging from 18-48 years of age in all risk categories . The Harmony Prenatal Test is available in more than 100 countries as a send-out test and has been used to guide clinical care in over 700,000 pregnancies worldwide.

1HarmonyTM is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis, and is considered a prenatal screening test, not a diagnostic test. Harmony™does not screen for potential chromosomal or genetic conditions other than those expressly identified in this document. Before making any treatment decisions, all women should discuss their results with their healthcare provider, who can recommend confirmatory, diagnostic testing where appropriate.2Norton, M., et al., N Engl J Med 2015; 372:1589-1597. Juneau et al. Fetal Diag Ther. 2014;36(4):282-6. Stokowski et al. Prenatal Diagnosis 2015; 35,1-4.

*The Harmony Prenatal Test is developed by Ariosa Diagnostics. Ariosa Diagnostics is a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). As with other laboratory-developed tests, this testing service has not been cleared or approved by the US FDA or any other federal regulatory agencies.Non-invasive prenatal testing (NIPT) services based on cell-free DNA analyses are not diagnostic; results should be confirmed by diagnostic testing.Data have not been submitted to or evaluated by Federal regulatory agencies and the test is not for sale as an In Vitro Diagnostic (IVD) in the US or the EU.